Marvel Biosciences Corp. develops novel therapies for autism spectrum disorder and related neurological and neurodevelopmental disorders through its wholly owned subsidiary, Marvel Biotechnology Inc. The company's lead therapeutic candidate, MB-204, is described as a fluorinated derivative of Istradefylline and an adenosine A2A receptor blocker.
Company news commonly covers MB-204 development, pediatric-friendly oral liquid formulation work, intellectual-property protection for purine compounds, scientific and partnering activity in neuroscience, and broader clinical or regulatory disclosures. Updates also reference potential disease areas tied to A2A receptor biology, including autism, depression, Alzheimer's disease, Rett syndrome and Fragile X syndrome, as well as capital-structure matters relevant to the public company.
Marvel Biosciences Corp. (TSXV: MRVL) has closed its non-brokered private placement, raising $500,000 through the issuance of 5,000,000 units at $0.10 per unit. Each unit comprises one common share and one warrant, exercisable at $0.15 per share until July 19, 2026. The company paid $25,200 in finders fees and issued 252,000 finder's warrants. Proceeds will fund pre-clinic experiments on MB-204 in chronic Alzheimer's disease and Autism models, and general working capital. The offering is subject to TSX Venture Exchange approval, with securities having a four-month hold period.
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) highlighted a new research paper published by Dr. David Blum, a member of their scientific advisory board. The study, published in 'Brain', discovered that early increases in adenosine A2A receptor (A2aR) in neurons can result in memory loss in Alzheimer's mouse models, specifically linked to Tau phosphorylation at the AT8 site rather than amyloid plaques. Marvel's lead asset, MB204, an A2aR antagonist, has shown promise in reducing Tau phosphorylation in initial studies. This suggests that MB204 could be a valuable approach in treating Alzheimer's.
Marvel Biosciences, through its subsidiary Marvel Biotechnology, focuses on developing new synthetic derivatives of off-patent drugs to target diseases like Alzheimer's, depression, anxiety, ADHD, cancer, and non-alcoholic steatohepatitis. By repurposing existing drugs, Marvel aims to reduce development time, cost, and risk.
On June 21, 2024, Marvel Biosciences (TSXV: MRVL) announced an update regarding its private placement unit offering. The TSX Venture Exchange (TSXV) has conditionally accepted Marvel's proposed non-brokered private placement, initially announced on May 16, 2024. Additionally, the company has been granted a two-week extension until July 17, 2024, to finalize its documentation related to the offering. This extension provides Marvel more time to complete necessary formalities for the private placement, which aims to raise funds for its ongoing business operations and research initiatives.
Marvel Biosciences announced a proposed non-brokered private placement of up to 10,000,000 units at $0.10 per unit, aiming to raise $1,000,000. Each unit includes one common share and one warrant, allowing purchase at $0.15 per share for two years. A triggering event could accelerate the warrant expiry. Finders may receive a fee up to 7% of the proceeds in cash and finder's warrants. The offering targets accredited investors and is subject to a four-month hold period and TSX Venture Exchange approval. Funds will support pre-clinic experiments on MB-204 for Alzheimer's and Autism models, and cover working capital.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.